Metachronous bilateral triple‑negative breast cancer associated with neurofibromatosis type 1: A case report

Yamagishi,Yoji; Einama,Takahiro; Yamasaki,Tamio; Koiwai,Tomomi; Hiratsuka,Miyuki; Fukumura,Makiko; Kono,Takako; Ueno,Hideki; Yamamoto,Junji; Tsuda,Hitoshi

doi:10.3892/ol.2019.9931

Metachronous bilateral triple‑negative breast cancer associated with neurofibromatosis type 1: A case report

Authors:
- Yoji Yamagishi
- Takahiro Einama
- Tamio Yamasaki
- Tomomi Koiwai
- Miyuki Hiratsuka
- Makiko Fukumura
- Takako Kono
- Hideki Ueno
- Junji Yamamoto
- Hitoshi Tsuda
View Affiliations

Affiliations: Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama 359‑8513, Japan, Department of Surgery, National Defense Medical College, Tokorozawa, Saitama 359‑8513, Japan
Published online on: January 14, 2019 https://doi.org/10.3892/ol.2019.9931
Pages: 2818-2824
Copyright: © Yamagishi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study reports a case of metachronous bilateral breast cancer associated with neurofibromatosis type 1 (NF1). A 67‑year‑old female, who had undergone a radical mastectomy of the left breast 34 years ago due to breast cancer, presented with a tumor of the right breast. The clinical stage of the original breast cancer was T2N0M0 stage IIA and adjuvant chemotherapy had not been not administered. With regard to the right‑sided breast tumor, on physical examination, multiple neurofibromas and café‑au‑lait spots were found to be scattered over the skin. A 2‑cm tumor was palpable. The preoperative histopathological diagnosis of the right‑sided breast tumor was invasive ductal carcinoma, T2N0M0 stage IIA, with negative results for hormone receptors and human epidermal growth factor receptor 2. The patient underwent a modified radical mastectomy and axillary node dissection, and received adjuvant chemotherapy. The bilateral tumors were similar in histology and immunophenotype, each being histological grade 3, triple‑negative and with a basal‑like subtype. Based on a literature review of 90 breast cancers in 84 patients with NF1 (84 patients, 90 breasts), younger age onset, advanced clinical stage and hormone receptor negativity were characteristic features. Bilateral cancer occurred in 8.3% of patients and was characterized by ER negativity, earlier stage and younger age compared with patients with unilateral cancer.

View Figures

View References

1	Yoshida Y, Kuramochi A, Ohta A, Furumura M, Imafuku S, Matsuo M, Chikuda H, Funasaki H, Saito K, Saya H, et al: Diagnostic criteria and treatment guidelines for nerve fibrosis type 1 (Recklinghausen's disease). Jpn J Dermatol. 118:1657–1666. 2008.(In Japanese).
2	Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, Fountain AM, Brereton A, Nicholson J and Mitchell AL: Type 1 neurofibromatosis gene: Identification of a large transcript disrupted in three NF1 patients. Science. 249:181–186. 1990. View Article : Google Scholar : PubMed/NCBI
3	Gottfried ON, Viskochil DH and Couldwell WT: Neurofibromatosis Type 1 and tumorigenesis: Molecular mechanisms and therapeutic implications. Neurosurg Focus. 28:E82010. View Article : Google Scholar : PubMed/NCBI
4	Korf BR: Malignancy in neurofibromatosis type 1. Oncologist. 5:477–485. 2000. View Article : Google Scholar : PubMed/NCBI
5	Uusitalo E, Kallionpää RA, Kurki S, Rantanen M, Pitkäniemi J, Kronqvist P, Härkönen P, Huovinen R, Carpen O, Pöyhönen M, et al: Breast cancer in neurofibromatosis type 1: Overrepresentation of unfavourable prognostic factors. Br J Cancer. 116:211–217. 2017. View Article : Google Scholar : PubMed/NCBI
6	Ceccaroni M, Genuardi M, Legge F, Lucci-Cordisco E, Carrara S, D'Amico F, Greggi S and Scambia G: BRCA1-related malignancies in a family presenting with von recklinghausen's disease. Gynecol Oncol. 86:375–378. 2002. View Article : Google Scholar : PubMed/NCBI
7	Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al: American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 134:907–922. 2010.PubMed/NCBI
8	Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 31:3997–4013. 2013. View Article : Google Scholar : PubMed/NCBI
9	Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, et al: Assessment of Ki67 in breast cancer: Recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst. 103:1656–1664. 2011. View Article : Google Scholar : PubMed/NCBI
10	Brierley JD, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumours. 8th. Wiley-Blackwell; Chichester: 2017
11	Salemis NS, Nakos G, Sambaziotis D and Gourgiotis S: Breast cancer associated with type 1 neurofibromatosis. Breast Cancer. 17:306–309. 2010. View Article : Google Scholar : PubMed/NCBI
12	Rasmussen SA and Friedman JM: NF1 gene and neurofibromatosis 1. Am J Epidemiol. 151:33–40. 2000. View Article : Google Scholar : PubMed/NCBI
13	Takano T, Kawashima T, Yamanouchi Y, Kitayama K, Ueno K and Hamaguchi H: Genetics of neurofibromatosis 1 in Japan: Mutation rate and paternal age effect. Hum Genetics. 89:281–286. 1992. View Article : Google Scholar
14	Sorensen SA, Mulvihill JJ and Nielsen A: Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med. 314:1010–1015. 1986. View Article : Google Scholar : PubMed/NCBI
15	Zoller ME, Rembeck B, Oden A, Samuelsson M and Angervall L: Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer. 79:2125–2131. 1997. View Article : Google Scholar : PubMed/NCBI
16	Sharif S, Moran A, Huson SM, Iddenden R, Shenton A, Howard E and Evans DG: Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet. 44:481–484. 2007. View Article : Google Scholar : PubMed/NCBI
17	Walker L, Thompson D, Easton D, Ponder B, Ponder M, Frayling I and Baralle D: A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer. 95:233–238. 2006. View Article : Google Scholar : PubMed/NCBI
18	Madanikia SA, Bergner A, Ye X and Blakeley JO: Increased risk of breast cancer in women with NF1. Am J Med Genet A. 158a:3056–3060. 2012. View Article : Google Scholar : PubMed/NCBI
19	Nakamura M, Tangoku A, Kusanagi H, Oka M and Suzuki T: Breast cancer associated with Recklinghausen's disease: Report of a case. Nihon Geka Hokan. 67:3–9. 1998.PubMed/NCBI
20	Murayama Y, Yamamoto Y, Shimojima N, Takahara T, Kikuchi K, Iida S and Kondo Y: T1 Breast cancer associated with von recklinghausen's neurofibromatosis. Breast Cancer. 6:227–230. 1999. View Article : Google Scholar
21	Xu GF, Lin B, Tanaka K, Dunn D, Wood D, Gesteland R, White R, Weiss R and Tamanoi F: The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell. 63:835–841. 1990. View Article : Google Scholar : PubMed/NCBI
22	Jeon YW, Kim RM, Lim ST, Choi HJ and Suh YJ: Early-onset breast cancer in a family with neurofibromatosis type 1 associated with a germline mutation in BRCA1. J Breast Cancer. 18:97–100. 2015. View Article : Google Scholar : PubMed/NCBI
23	Campos B, Balmana J, Gardenyes J, Valenzuela I, Abad O, Fàbregas P, Volpini V and Díez O: Germline mutations in NF1 and BRCA1 in a family with neurofibromatosis type 1 and early-onset breast cancer. Breast Cancer Res Treat. 139:597–602. 2013. View Article : Google Scholar : PubMed/NCBI
24	Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, Garber JE, Kauff ND, Khan S, Klein C, et al: NCCN Guidelines insights: Genetic/familial high-risk assessment: Breast and ovarian, version 2.2017. J Natl Compr Canc Netw. 15:9–20. 2017. View Article : Google Scholar : PubMed/NCBI